<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00878657</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000639635</org_study_id>
    <secondary_id>P30CA072720</secondary_id>
    <secondary_id>CINJ-070805</secondary_id>
    <secondary_id>0220090024</secondary_id>
    <nct_id>NCT00878657</nct_id>
  </id_info>
  <brief_title>Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase I/II Radiotherapy Dose Escalation Study in Locally Advanced Pancreatic Cancer, Using a Simultaneous Intensity Modulated Boost With Concurrent Gemcitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to&#xD;
      the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in&#xD;
      chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. Giving intensity-modulated&#xD;
      radiation therapy together with gemcitabine may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of&#xD;
      intensity-modulated radiation therapy and to see how well it works when given together with&#xD;
      gemcitabine in treating patients with locally advanced pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was terminated early due to slow accrual and only the phase I portion of hte study&#xD;
      was opened. The phase of the study has been revised to only a phase I study.&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the maximum tolerated dose (MTD) of intensity-modulated radiotherapy&#xD;
           delivered to the gross tumor volume when administered with gemcitabine hydrochloride in&#xD;
           patients with locally advanced pancreatic carcinoma. (Phase I)&#xD;
&#xD;
        -  To define the dose-limiting toxicities of this regimen in these patients. (Phase I)&#xD;
&#xD;
        -  To determine the local control in patients treated at the MTD (determined in phase I).&#xD;
           (Phase II)&#xD;
&#xD;
        -  To compare the disease-free survival and time to progression in these patients with that&#xD;
           of historical controls. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a multicenter phase I, dose-escalation study of intensity-modulated&#xD;
      radiotherapy, followed by a phase II study.&#xD;
&#xD;
        -  Induction chemotherapy: Patients receive gemcitabine hydrochloride IV on days 1, 8, and&#xD;
           15. Treatment repeats every 28 days for 2 courses in the absence of disease progression&#xD;
           or unacceptable toxicity. Patients then undergo CT scan. Patients with no evidence of&#xD;
           metastatic disease proceed to chemoradiotherapy.&#xD;
&#xD;
        -  Chemoradiotherapy: Beginning 1-2 weeks after completion of induction chemotherapy,&#xD;
           patients undergo intensity-modulated radiotherapy once daily 5 days a week and&#xD;
           gemcitabine hydrochloride IV over 30 minutes once weekly for 5 weeks in the absence of&#xD;
           disease progression or unacceptable toxicity. Patients whose disease remains&#xD;
           unresectable proceed to adjuvant chemotherapy.&#xD;
&#xD;
        -  Adjuvant chemotherapy: Beginning 4-6 weeks after completion of chemoradiotherapy,&#xD;
           patients receive gemcitabine hydrochloride as in induction chemotherapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year, every 6&#xD;
      months for 2 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual&#xD;
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of intensity-modulated radiotherapy (Phase I)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (Phase II)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival (Phase II)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy plus gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: gemcitabine hydrochloride&#xD;
Radiation: intensity-modulated radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.</description>
    <arm_group_label>Radiotherapy plus gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Dose escalation levels (cohorts) for this study:&#xD;
Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy</description>
    <arm_group_label>Radiotherapy plus gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Pathologically confirmed adenocarcinoma or poorly differentiated carcinoma of the&#xD;
             pancreas, ampulla of Vater, or distal bile duct&#xD;
&#xD;
               -  Locally advanced disease&#xD;
&#xD;
               -  Medically inoperable, unresectable, or borderline resectable disease&#xD;
&#xD;
                    -  No previously resected disease (i.e., status post-pancreaticoduodenotomy)&#xD;
&#xD;
          -  No non-adenocarcinoma, adenosquamous carcinoma, islet cell carcinoma, cyst adenoma,&#xD;
             cystadenocarcinoma, carcinoid tumor, or duodenal carcinoma&#xD;
&#xD;
          -  No lesions in the tail of the pancreas and/or splenic artery/vein&#xD;
             involvement/encasement&#xD;
&#xD;
          -  No recurrent or metastatic (M1) disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  WBC &gt; 3,000/μL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/μL&#xD;
&#xD;
          -  Bilirubin ≤ 2 mg/dL&#xD;
&#xD;
          -  SGOT &lt; 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Adequate oral nutrition (e.g., ≥ 1,500 calories/day, stable weight for ≥ 2 weeks, and&#xD;
             ≤ 5% weight loss)&#xD;
&#xD;
          -  No active malignancy within the past 3 years, except cervical carcinoma in situ or&#xD;
             nonmelanoma skin cancer that has been removed&#xD;
&#xD;
          -  No severe, active comorbidity, including any of the following:&#xD;
&#xD;
               -  Unstable angina and/or congestive heart failure requiring hospitalization within&#xD;
                  the past 6 months&#xD;
&#xD;
               -  Transmural myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Acute bacterial or fungal infection requiring IV antibiotics at the time of study&#xD;
                  registration&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness&#xD;
                  requiring hospitalization within the past month or precluding study therapy at&#xD;
                  the time of study registration&#xD;
&#xD;
               -  Active hepatitis, decompensated cirrhosis, or clinically significant liver&#xD;
                  failure&#xD;
&#xD;
               -  Other severe comorbid condition, as determined by the principal investigator&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No prior radiotherapy to any upper abdominal site&#xD;
&#xD;
          -  No concurrent prophylactic colony-stimulating factors during radiotherapy&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
&#xD;
          -  No other concurrent chemotherapy, immunotherapy, hormonal cancer therapy,&#xD;
             radiotherapy, surgery for cancer, or experimental therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salma Jabbour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>April 8, 2009</study_first_submitted>
  <study_first_submitted_qc>April 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2009</study_first_posted>
  <last_update_submitted>May 1, 2014</last_update_submitted>
  <last_update_submitted_qc>May 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

